Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 92

Sort by

Sort Order Select

Journal Articles

Transfusion independence with momelotinib regardless of baseline erythropoietin levels in the Phase 3 SIMPLIFY-1 trial

Stephen Oh, Juan Carlos Hernandez Boluda, Jean-Jacques Kiladjian, Viviane Dubruille, Christian Recher, Alexandre Lockhart, Chandan Kumar, Hanny Musa, Jasmine Sahni, Dwaipayan Patnaik, Claire Harrison

Blood (2025) 146 (Supplement 1): 2025.

https://doi.org/10.1182/blood-2025-2025

Published: 2025

Journal Articles

Fedora preliminary analysis of a Phase II study evaluating the tolerability, safety and activity of fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis.

Blood (2025) 146 (Supplement 1): 486.

https://doi.org/10.1182/blood-2025-486

Published: 2025

Journal Articles

Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): Preliminary results from dose escalation of two global Phase 1 studies

Blood (2025) 146 (Supplement 1): 484.

https://doi.org/10.1182/blood-2025-484

Published: 2025

Journal Articles

Preliminary data from the Phase I/II study of nuvisertib, an oral investigational selective PIM1 inhibitor, in combination with momelotinib showed clinical responses in patients with relapsed/refractory myelofibrosis

Blood (2025) 146 (Supplement 1): 482.

https://doi.org/10.1182/blood-2025-482

Published: 2025

Journal Articles

Multi-dimensional adherence patterns in rare haematological conditions: Longitudinal analysis of real-world patient-reported outcomes

Kim Summers, Orlando Agrippa, Andrea Preston, Muna Yusuf, Tushar Singh, Georgina O'Neill, Claire Harrison, Patrick Harrington, Shirley D'Sa, Paul Telfer, Sanne Lugthart

Blood (2025) 146 (Supplement 1): 7973.

https://doi.org/10.1182/blood-2025-7973

Published: 2025

Journal Articles

Safety and efficacy of INCA033989, a novel first in class mutant calreticulin-specific monoclonal antibody, in patients with essential thrombocythemia

Blood (2025) 146 (Supplement 1): 1024.

https://doi.org/10.1182/blood-2025-1024

Published: 2025

Journal Articles

Molecular characterization of patients (pts) with myeloproliferative neoplasms treated with INCA033989 demonstrates selective targeting of CALR mutant hematopoietic cells

Bethan Psaila, Jyoti Nangalia, Jason Gotlib, Claire Harrison, John Mascarenhas, Erin Crowgey, Betty Lamothe, Chenwei Tian, Evan Braunstein, Steffen Koschmieder

Blood (2025) 146 (Supplement 1): 71.

https://doi.org/10.1182/blood-2025-71

Published: 2025

Journal Articles

Multi-endpoint AI morphology model (MEAM) enhances risk prediction for vascular events and disease progression in MPNs

Blood (2025) 146 (Supplement 1): 5599.

https://doi.org/10.1182/blood-2025-5599

Published: 2025

Journal Articles

Correlation between interleukin (IL)-8 and tumor necrosis factor (TNF)-alpha levels and overall survival in patients (pts) with myelofibrosis (MF) relapsed or refractory (R/R) to a Janus-associated kinase inhibitor (JAKi) treated with imetelstat (IME) in the imbark trial

John Mascarenhas, Claire Harrison, Alessandro Lucchesi, Angela Fleischman, Rami Komrokji, Alessandro Maria Vannucchi, Jean-Jacques Kiladjian, Yiqun Yang, Libo Sun, Ying Wan, Michelle Mudge-Riley, Tymara Berry, Faye Feller, Fei Huang, Prithviraj Bose

Blood (2025) 146 (Supplement 1): 5585.

https://doi.org/10.1182/blood-2025-5585

Published: 2025

Journal Articles

Durable efficacy and long-term safety with pelabresib plus ruxolitinib in JAK Inhibitor–Naive myelofibrosis: 96-week Results from the Phase III MANIFEST-2 study

Blood (2025) 146 (Supplement 1): 910.

https://doi.org/10.1182/blood-2025-910

Published: 2025

Journal Articles

Hematological and clinical improvements with elritercept (KER-050, TAK-226) at the recommended Phase 2 dose (RP2D) in patients with myelofibrosis (MF) receiving ruxolitinib: Updated results from the Phase 2 restore trial

Ciro Rinaldi, David Ross, Lynette Chee, Alessandra Iurlo, Chun Teh, Francesca Palandri, Maria Laura Fox, Jennifer O'Sullivan, Marco Brociner, Jen Salstrom, Xin Tong, Varsha Sundaresan, Leopold Sellner, Katsuhiro Togami, Claire Harrison

Blood (2025) 146 (Supplement 1): 909.

https://doi.org/10.1182/blood-2025-909

Published: 2025

Journal Articles

Interim analysis of promise, a clinical study combining the BET inhibitor OPN-2853 with ruxolitinib in patients with advanced myelofibrosis experiencing an inadequate response to ruxolitinib

Blood (2025) 146 (Supplement 1): 3794.

https://doi.org/10.1182/blood-2025-3794

Published: 2025

Journal Articles

Role of allo-HCT in “nonclassical” MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT

Nicola Polverelli, Juan Carlos Hernández-Boluda, Francesco Onida, Carmelo Gurnari, Kavita Raj, Tomasz Czerw, Michelle Kenyon, Marie Robin, Katja Sockel, Annalisa Ruggeri, Isabel Sánchez-Ortega, Daniel A. Arber, Luca Arcaini, Fernando Barroso Duarte, Giorgia Battipaglia, Yves Chalandon, Fabio Ciceri, Nicholas C. P. Cross, Joanna Drozd-Sokolowska, Vaneuza Funke, Nico Gagelmann, Naseema Gangat, Jason Gotlib, Paola Guglielmelli, Claire Harrison, Gabriela Hobbs, Tania Jain, Joseph D. Khoury, Jean Jacques Kiladjian, Nicolaus Kröger, Luca Malcovati, Massimo Martino, Ruben Mesa, Attilio Orazi, Eric Padron, Francesca Palandri, Francesco Passamonti, Mrinal M. Patnaik, Naveen Pemmaraju, Deepti H. Radia, Andreas Reiter, Domenico Russo, Christof Scheid, Ayalew Tefferi, Alessandro M. Vannucchi, Daniel H. Wiseman, Ibrahim Yakoub-Agha, Donal P. McLornan

Blood (2025) 145 (22): 2561–2573.

https://doi.org/10.1182/blood.2024028000

Published: 2025

Includes: Supplemental data

Journal Articles

New Criteria for Evaluating Outcomes of Myelofibrosis Therapy

Monia Marchetti, Alessandro Maria Vannucchi, John O. Mascarenhas, Alberto Alvarez-Larran, Prithviraj Bose, Robert Peter Gale, Claire Harrison, Rüdiger Hehlmann, Jean-Jacques Kiladjian, Steffen Koschmieder, Ruben Mesa, Francesco Passamonti, Alessandro Rambaldi, Ayalew Tefferi, Tiziano Barbui

Blood (2024) 144 (Supplement 1): 7898.

https://doi.org/10.1182/blood-2024-198646

Published: 2024

Journal Articles

Real World Efficacy and Safety of Momelotinib for Myelofibrosis: Evaluation of a UK-Wide Study Confirms 40% Anaemia Response Rate in a Non-Clinical Trial Cohort

Blood (2024) 144 (Supplement 1): 1804.

https://doi.org/10.1182/blood-2024-207251

Published: 2024

Journal Articles

POIESIS: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Phase 3 Study of Navtemadlin As Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Pankit Vachhani, Raajit Rampal, Terrence Bradley, Claire Harrison, Tania Jain, Andrew T. Kuykendall, Francesca Palandri, John O. Mascarenhas, Haifa Kathrin Al-Ali, Francesco Passamonti, Anna Nekhymchuk, Hilarie Foss, Wayne Rothbaum, Srdan Verstovsek, Florian Heidel

Blood (2024) 144 (Supplement 1): 1808.2.

https://doi.org/10.1182/blood-2024-200966

Published: 2024

Journal Articles

Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed or Refractory to Janus Kinase Inhibitor in IMpactMF, a Randomized, Open-Label, Phase 3 Trial

John O. Mascarenhas, Claire Harrison, Prithviraj Bose, Jean-Jacques Kiladjian, Alessandro Lucchesi, Alessandro Maria Vannucchi, Tymara Berry, Jennifer Riggs, Lixian Peng, Fei Huang, Ying Wan, Vivian Rodolf, Judy Ho, Shyamala Navada, Rami S. Komrokji

Blood (2024) 144 (Supplement 1): 1808.1.

https://doi.org/10.1182/blood-2024-199235

Published: 2024

Journal Articles

Treatment of Myeloproliferative Neoplasms with Janus Kinase Inhibitors: A Meta-Analysis of Cardiovascular Safety

Edouard Long, Roberta Dunn, Laura Li Gagnon, Claire Harrison, Yunfan Yang, Jennifer O'Sullivan

Blood (2024) 144 (Supplement 1): 3168.

https://doi.org/10.1182/blood-2024-202359

Published: 2024

Journal Articles

Odyssey: A Phase 2 Open-Label Study of Momelotinib in Combination with Luspatercept in Patients with Transfusion-Dependent Myelofibrosis

Prithviraj Bose, Aaron T. Gerds, Vikas Gupta, Bryan Strouse, Bharat Patel, Catherine Ellis, Claire Harrison

Blood (2024) 144 (Supplement 1): 3191.2.

https://doi.org/10.1182/blood-2024-205767

Published: 2024

Journal Articles

Mympnvoice - a Novel Smartphone App for Monitoring Patient Reported Outcomes and Biometric Data in Patients with Myeloproliferative Neoplasms

Patrick Harrington, Kim Summers, Andrea Preston, Debbie Street, Mark Taylor, Amna Sheikh, Muna Yusuf, Rebecca Frewin, Louise Wallis, Catherine Loughran, Jennifer O'Sullivan, Claire Woodley, Priya Sriskandarajah, Samah Alimam, Alesia Khan, Andrea Duminuco, Shahram Kordasti, Orlando Agrippa, Claire Harrison

Blood (2024) 144 (Supplement 1): 4557.

https://doi.org/10.1182/blood-2024-205372

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Transfusion independence with momelotinib regardless of baseline erythropoietin levels in the Phase 3 SIMPLIFY-1 trial

Fedora preliminary analysis of a Phase II study evaluating the tolerability, safety and activity of fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis.

Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): Preliminary results from dose escalation of two global Phase 1 studies

Preliminary data from the Phase I/II study of nuvisertib, an oral investigational selective PIM1 inhibitor, in combination with momelotinib showed clinical responses in patients with relapsed/refractory myelofibrosis

Multi-dimensional adherence patterns in rare haematological conditions: Longitudinal analysis of real-world patient-reported outcomes

Safety and efficacy of INCA033989, a novel first in class mutant calreticulin-specific monoclonal antibody, in patients with essential thrombocythemia

Molecular characterization of patients (pts) with myeloproliferative neoplasms treated with INCA033989 demonstrates selective targeting of CALR mutant hematopoietic cells

Multi-endpoint AI morphology model (MEAM) enhances risk prediction for vascular events and disease progression in MPNs

Correlation between interleukin (IL)-8 and tumor necrosis factor (TNF)-alpha levels and overall survival in patients (pts) with myelofibrosis (MF) relapsed or refractory (R/R) to a Janus-associated kinase inhibitor (JAKi) treated with imetelstat (IME) in the imbark trial

Durable efficacy and long-term safety with pelabresib plus ruxolitinib in JAK Inhibitor–Naive myelofibrosis: 96-week Results from the Phase III MANIFEST-2 study

Hematological and clinical improvements with elritercept (KER-050, TAK-226) at the recommended Phase 2 dose (RP2D) in patients with myelofibrosis (MF) receiving ruxolitinib: Updated results from the Phase 2 restore trial

Interim analysis of promise, a clinical study combining the BET inhibitor OPN-2853 with ruxolitinib in patients with advanced myelofibrosis experiencing an inadequate response to ruxolitinib

Role of allo-HCT in “nonclassical” MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT

New Criteria for Evaluating Outcomes of Myelofibrosis Therapy

Real World Efficacy and Safety of Momelotinib for Myelofibrosis: Evaluation of a UK-Wide Study Confirms 40% Anaemia Response Rate in a Non-Clinical Trial Cohort

POIESIS: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Phase 3 Study of Navtemadlin As Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed or Refractory to Janus Kinase Inhibitor in IMpactMF, a Randomized, Open-Label, Phase 3 Trial

Treatment of Myeloproliferative Neoplasms with Janus Kinase Inhibitors: A Meta-Analysis of Cardiovascular Safety

Odyssey: A Phase 2 Open-Label Study of Momelotinib in Combination with Luspatercept in Patients with Transfusion-Dependent Myelofibrosis

Mympnvoice - a Novel Smartphone App for Monitoring Patient Reported Outcomes and Biometric Data in Patients with Myeloproliferative Neoplasms

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only